CHMP recommends RYBREVANT®? (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small…

Posted: July 29, 2024 at 2:33 am

Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib1,2,3,4 ?

Follow this link:
CHMP recommends RYBREVANT®? (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small...

Related Posts